Effects of combined radiosurgery and temozolomide therapy on epidermal growth factor receptor and variant III in glioblastoma multiforme

Lin,Yiguang; Zhou,Junhu; Xu,Jianglong; Zhao,Kai; Liu,Xiaomin; Wang,Guokai; Zhang,Zhiyuan; Ge,Youlin; Zong,Yongqing; Xu,Desheng; Tan,Yanli; Fang,Chuan; Kang,Chunsheng

doi:10.3892/ol.2018.8055

Effects of combined radiosurgery and temozolomide therapy on epidermal growth factor receptor and variant III in glioblastoma multiforme

Authors:
- Yiguang Lin
- Junhu Zhou
- Jianglong Xu
- Kai Zhao
- Xiaomin Liu
- Guokai Wang
- Zhiyuan Zhang
- Youlin Ge
- Yongqing Zong
- Desheng Xu
- Yanli Tan
- Chuan Fang
- Chunsheng Kang
View Affiliations

Affiliations: Gamma Knife Centre, Department of Neurosurgery, The Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China, Tianjin Neurological Institute, Department of Neurosurgery, Tianjin Medical University, General Hospital and Laboratory of Neurooncology, Tianjin 300052, P.R. China, Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding, Hebei 071000, P.R. China, Gamma Knife Centre, Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin 300350, P.R. China
Published online on: February 14, 2018 https://doi.org/10.3892/ol.2018.8055
Pages: 5751-5759
Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma multiforme (GBM) is a highly malignant and notably aggressive primary tumour. Variant III of the epidermal growth factor receptor (EGFRvIII) is one of the most common types of variants in GBM, and serves an important role in tumour invasion, proliferation and treatment resistance. In the present study, statistical analyses were performed on data from 57 patients with GBM, and polymerase chain reaction detection was conducted on the tumour tissues from 32 of these patients. The results indicated that the EGFRvIII mutation was significantly associated with tumour malignancy. Human GBMU87-EGFRvIII cell lines were cultured and treated with radiosurgery and temozolomide individually, or with combined radiosurgery and temozolomide treatment. In vitro and in vivo experimental methods were used to detect the expression levels of Ki‑67 and EGFRvIII. As verified in the present study, the EGFRvIII mutation is positively correlated with the malignancy of tumours, and combined radiosurgery and temozolomide therapy may inhibit the invasion and proliferation abilities of U87‑ EGFRvIII more effectively than treatment alone.

View Figures

View References

1	Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al: Malignant astrocytic glioma: Genetics biology, and paths to treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
2	Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK and DePinho RA: Malignant glioma: Genetics and biology of a grave matter. Genes Dev. 15:1311–1333. 2001. View Article : Google Scholar : PubMed/NCBI
3	Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
4	Jin X, Yin J, Kim SH, Sohn YW, Beck S, Lim YC, Nam DH, Choi YJ and Kim H: EGFR-AKT Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res. 71:7125–7134. 2011. View Article : Google Scholar : PubMed/NCBI
5	Jeon HM, Kim SH, Jin X, Park JB, Kim SH, Joshi K, Nakano I and Kim H: Cross talk between glioma-initiating cells and endothelial cells drives tumor progression. Cancer Res. 74:4482–4492. 2014. View Article : Google Scholar : PubMed/NCBI
6	Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL and Wong AJ: Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55:5536–5539. 1995.PubMed/NCBI
7	Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A and Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 313:144–147. 1985. View Article : Google Scholar : PubMed/NCBI
8	Hatanpaa KJ, Burma S, Zhao D and Habib AA: Epidermal growth factor receptor in glioma: Signal transduction, neuropathology, imaging, and radioresistance. Neoplasia. 12:675–684. 2010. View Article : Google Scholar : PubMed/NCBI
9	Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, et al: Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 25:2288–2294. 2007. View Article : Google Scholar : PubMed/NCBI
10	Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, et al: Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res. 14:488–493. 2008. View Article : Google Scholar : PubMed/NCBI
11	Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
12	Jia Q, Li Y, Xu D, Li Z, Zhang Z, Zhang Y, Liu D, Liu X, Pu P and Kang C: Radiosensitivity of glioma to Gamma Knife treatment enhanced in vitro and in vivo by RNA interfering Ku70 that is mediated by a recombinant adenovirus. J Neurosurg. 113 Suppl:S228–S235. 2010.
13	Madani I, De Neve W and Mareel M: Does ionizing radiation stimulate cancer invasion and metastasis? Bull Cancer. 95:292–300. 2008.PubMed/NCBI
14	Ge H, Gong X and Tang CK: Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer. 98:357–361. 2002. View Article : Google Scholar : PubMed/NCBI
15	Olapade-Olaopa EO, Moscatello DK, MacKay EH, Horsburgh T, Sandhu DP, Terry TR, Wong AJ and Habib FK: Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer. 82:186–194. 2000. View Article : Google Scholar : PubMed/NCBI
16	Khattri A, Zuo Z, Brägelmann J, Keck MK, El Dinali M, Brown CD, Stricker T, Munagala A, Cohen EE, Lingen MW, et al: Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncol. 51:53–58. 2015. View Article : Google Scholar : PubMed/NCBI
17	Tan Y, Shi YS, Wu XD, Liang HY, Gao YB, Li SJ, Zhang XM, Wang F and Gao TM: DNA aptamers that target human glioblastomamultiforme cells overexpressing epidermal growth factor receptor variant III in vitro. Acta Pharmacol Sin. 34:1491–1498. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kim J, Lee JS, Jung J, Lim I, Lee JY and Park MJ: Emodin suppresses maintenance of stemness by augmenting proteosomal degradation of epidermal growth factor receptorepidermal growth factor receptor variant III in glioma stem cells. Stem Cells Dev. 24:284–295. 2015. View Article : Google Scholar : PubMed/NCBI
19	Congdon KL, Gedeon PC, Suryadevara CM, Caruso HG, Cooper LJ, Heimberger AB and Sampson JH: Epidermal growth factor receptor and variant III targeted immunotherapy. Neuro Oncol. 16 Suppl 8:viii20–viii25. 2014. View Article : Google Scholar : PubMed/NCBI
20	Zhang X, Liang H, Tan Y, Wu X, Li S and Shi Y: U87-EGFRvIII cell-specific aptamer mediates small interfering RNA delivery. Biomed Rep. 2:495–499. 2014. View Article : Google Scholar : PubMed/NCBI
21	Kim EJ, Kim SO, Jin X, Ham SW, Kim J, Park JB, Lee JY, Kim SC and Kim H: Epidermal growth factor receptor variant III renders glioma cancer cells less differentiated by JAGGED1. Tumour Biol. 36:2921–2928. 2015. View Article : Google Scholar : PubMed/NCBI
22	Katanasaka Y, Kodera Y, Kitamura Y, Morimoto T, Tamura T and Koizumi F: Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma. Mol Cancer. 12:312013. View Article : Google Scholar : PubMed/NCBI
23	Senft C, Bink A, Franz K, Vatter H, Gasser T and Seifert V: Intraoperative MRI guidance and extent of resection in glioma surgery: A randomised, controlled trial. Lancet Oncol. 12:997–1003. 2011. View Article : Google Scholar : PubMed/NCBI
24	Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, et al: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 370:699–708. 2014. View Article : Google Scholar : PubMed/NCBI
25	Binello E, Green S and Germano IM: Radiosurgery for high-grade glioma. Surg Neurol Int. 3 Suppl 2:S118–S126. 2012. View Article : Google Scholar : PubMed/NCBI
26	Waters JD, Rose B, Gonda DD, Scanderbeg DJ, Russell M, Alksne JF, Murphy K, Carter BS, Lawson J and Chen CC: Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma. J Neurooncol. 113:467–477. 2013. View Article : Google Scholar : PubMed/NCBI
27	Kwak SY, Kim BY, Ahn HJ, Yoo JO, Kim J, Bae IH and Han YH: Ionizing radiation-inducible miR-30e promotes glioma cell invasion through EGFR stabilization by directly targeting CBL-B. FEBS J. 282:1512–1525. 2015. View Article : Google Scholar : PubMed/NCBI
28	Zhang X, Li X, Zhang N, Yang Q and Moran MS: Low doses ionizing radiation enhances the invasiveness of breast cancer cells by inducing epithelial-mesenchymal transition. Biochem Biophys Res Commun. 412:188–192. 2011. View Article : Google Scholar : PubMed/NCBI
29	Iuchi T, Hatano K, Uchino Y, Itami M, Hasegawa Y, Kawasaki K, Sakaida T and Hara R: Methionine Uptake and required radiation dose to control glioblastoma. Int J Radiat Oncol Biol Phys. 93:133–140. 2015. View Article : Google Scholar : PubMed/NCBI
30	Hawkins-Daarud A, Rockne R, Corwin D, Anderson AR, Kinahan P and Swanson KR: In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma. J R Soc Interface. 12:201503882015. View Article : Google Scholar : PubMed/NCBI
31	Krauze AV, Myrehaug SD, Chang MG, Holdford DJ, Smith S, Shih J, Tofilon PJ, Fine HA and Camphausen K: A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma. Int J Radiat Oncol Biol Phys. 92:986–992. 2015. View Article : Google Scholar : PubMed/NCBI